UPS extends pharma network

UPS customers can now ship biological substances, dangerous goods in excepted quantities and shipments using dry ice to more than 20 additional international destinations.
The US-based global express and logistics’ operator says that the expansion is a direct response to a growing demand from biopharmaceutical manufacturers, diagnostics companies, laboratories and distributors.  
“The UPS global transportation network has been enhanced to move biological specimens to and from more than 50 countries around the world,” said John Menna, UPS vice president of global strategy, healthcare logistics.
“The expanded programme was guided by our customers to include the locations that are most important to them.”
UPS is now able to pick up and deliver packages under regulation UN3373 (Biologic Substances, Category B, Diagnostic Specimen and Clinical Specimen) as well as UN1845 (Carbon Dioxide, solid or dry ice) in Australia, Bulgaria, Croatia, Estonia, India, Indonesia, Israel, Latvia, Lithuania, New Zealand, Panama, Romania, Russia, Saudi Arabia, Slovakia, Slovenia, South Africa, Taiwan, Turkey and Ukraine.
UN3373 and UN1845 are guidelines issued by the International Air Transport Association (IATA) to regulate the safe transportation of goods using air transportation modes.